1.A Case of Obstructive Jaundice-associated Pruritus Which Was not Improved by an Antihistamine and a Selective Serotonin Reuptake Inhibitor Treatment, but Was Responded to Nalfurafine Hydrochloride
Yoshito Yoshikawa ; Yoshinobu Matsuda ; Sachiko Okayama ; Juri Nimura ; Minako Doi ; Shinobu Nagata
Palliative Care Research 2017;12(1):506-510
Introduction: We encountered a patient in whom pruritus was induced by obstructive jaundice associated with metastatic liver cancer. Nalfurafine hydrochloride, a selective κ receptor agonist, improved the patient’s pruritus. Case Presentation: The patient was a 70-year-old woman who developed metastatic liver tumor-associated jaundice after surgery for colorectal cancer. She developed pruritus, which was not improved by an antihistamine or a selective serotonin reuptake inhibitor treatment. Nalfurafine was administered for suspected central pruritus. The numerical rating scale for pruritus improved from 9 to 3. Discussion: Compared to other skin diseases such as urticaria and atopic dermatitis, pruritus that accompanies a systemic disease such as chronic renal failure and liver disease does not respond to existing therapeutic drugs in many patients. Chronic liver disease-associated pruritus is intractable and central. Pruritus through central and peripheral mechanisms was mixed in this patient; however, central pruritus may have been dominant. The antipruritic effect of nalfurafine has been confirmed. It may be an effective therapeutic drug for obstructive jaundice-associated pruritus.